Reducing the incidence of pancreatic cancer through radiofrequency ablation of mucinous cystic neoplasms: What is the evidence?
Best Practice & Research Clinical Gastroenterology · 2025
DOI: 10.1016/j.bpg.2025.101986 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2025. Verfasst von Pujitha Kudaravalli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology & Hepatology, Lahey Hospital & Medical Center, Burlington, MA, United States. Electronic address: pkudaravalli17@gmail.com. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Radiofrequency Ablation, Pancreatic Cyst, Neoplasms, Cystic, Mucinous, and Serous. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic cystic lesions are mostly discovered incidentally during cross-sectional imaging for other indications. They range from benign cysts to premalignant lesions, posing a risk for development of pancreatic cancer. Surveillance of cysts with low-risk features and surgical resection of high-risk ones has been the standard of care. However, the lack of consensus between national society guidelines results in discordant management and follow-up. One of the upcoming therapeutic modalities for pancreatic cysts, including mucinous cystic neoplasms (MCN), is endoscopic ultrasound (EUS)-guided interventions, including injection of chemotherapeutic agents or EUS-guided radiofrequency ablation (EUS-RFA). EUS-RFA is emerging as a promising minimally invasive tool with the need for further investigation to understand its clinical utility. This review discusses the physiology, clinical studies, adverse events, and future perspectives of RFA for various pancreatic lesions, with particular regard with MCN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology & Hepatology, Lahey Hospital & Medical Center, Burlington, MA, United States. Electronic address: pkudaravalli17@gmail.com.
- Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD, 21215, United States. Electronic address: sahibs559@gmail.com.
- Gastroenterology & Hepatology, Sinai Hospital of Baltimore, Baltimore, MD, 21215, United States. Electronic address: rvinayek@hotmail.com.
- Gastroenterology & Hepatology, State University of New York Upstate Medical University, Syracuse, NY, United States. Electronic address: aswathg@upstate.edu.
- Diagnostic and Interventional Endoscopy of Pancreas, The Pancreas Institute, University of Verona, 37134, Verona, Italy. Electronic address: stefanocrino@hotmail.com.
- Division of Gastroenterology, Michigan Medicine, University of Michigan, Ann Arbor, MI, United States. Electronic address: machicad@med.umich.edu.
Zitieren
APA
Kudaravalli, P., Singh, S., Vinayek, R., Aswath, G., Crinò, S. F., Machicado, J., & Facciorusso, A. (2025). Reducing the incidence of pancreatic cancer through radiofrequency ablation of mucinous cystic neoplasms: What is the evidence?. Best Practice & Research Clinical Gastroenterology. https://doi.org/10.1016/j.bpg.2025.101986
Vancouver
Kudaravalli P, Singh S, Vinayek R, Aswath G, Crinò SF, Machicado J, et al. Reducing the incidence of pancreatic cancer through radiofrequency ablation of mucinous cystic neoplasms: What is the evidence?. Best Practice & Research Clinical Gastroenterology. 2025. doi:10.1016/j.bpg.2025.101986
BibTeX
@article{Kudaravalli2025,
author = {Kudaravalli, Pujitha and Singh, Sahib and Vinayek, Rakesh and Aswath, Ganesh and Crinò, Stefano Francesco and Machicado, Jorge and Facciorusso, Antonio},
title = {Reducing the incidence of pancreatic cancer through radiofrequency ablation of mucinous cystic neoplasms: What is the evidence?},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2025},
doi = {10.1016/j.bpg.2025.101986}
}
EUVIMED